Literature DB >> 29778547

Relation of inflammatory markers with symptoms of psychotic disorders: a large cohort study.

E J Liemburg1, I M Nolte2, H C Klein3, H Knegtering4.   

Abstract

AIMS: Immunological mechanisms may play a role in symptomatology of patients with a psychotic disorder. Besides metabolic problems and medication use, inflammatory processes that may occur due to the disorder may cause increased inflammatory markers and concurrent psychiatric symptoms. The aim of this study is to investigate whether levels of C-reactive protein (CRP) and white blood cell count (WBC) are related to positive and negative symptoms of psychotic disorders, and whether age, gender, duration of illness, smoking behavior, haloperidol equivalents, mediation use, body mass, and metabolic syndrome affect this relation.
METHODS: CRP and WBC values of 2123 patients with a psychotic disorder were related to positive and negative symptoms measured with a psychiatric interview. CRP was analyzed by survival analysis accounting for detection limit and WBC by linear mixed model analysis. In case of a significant association, the confounding factors were added to the model.
RESULTS: Both WBC and CRP were related to both positive and negative symptoms, even after correction for age, gender, smoking, use of medication and metabolic problems. Of the covariates, gender, metabolic problems, smoking and statins also showed a strong association with inflammatory markers.
CONCLUSIONS: This study in a large patient-group confirmed that inflammatory markers are related to psychotic disorders, particularly negative symptoms. Future studies could use more precise measures of inflammatory markers and measure symptomatic state at specific moments in illness progression.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRP; Inflammation; Psychotic disorder; Symptoms; WBC

Mesh:

Substances:

Year:  2018        PMID: 29778547     DOI: 10.1016/j.pnpbp.2018.04.006

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  11 in total

1.  Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta-analysis.

Authors:  Amedeo Minichino; Morwenna Senior; Natascia Brondino; Sam H Zhang; Beata R Godwlewska; Philip W J Burnet; Andrea Cipriani; Belinda R Lennox
Journal:  JAMA Psychiatry       Date:  2019-09-01       Impact factor: 21.596

Review 2.  Brick by Brick: Building a Transdiagnostic Understanding of Inflammation in Psychiatry.

Authors:  David S Thylur; David R Goldsmith
Journal:  Harv Rev Psychiatry       Date:  2022 Jan-Feb 01       Impact factor: 3.732

3.  Risk factors for metabolic syndrome in individuals with recent-onset psychosis at disease onset and after 1-year follow-up.

Authors:  Yolanda Alonso; Carmen Miralles; M José Algora; Alba Valiente-Pallejà; Vanessa Sánchez-Gistau; Gerard Muntané; Javier Labad; Elisabet Vilella; Lourdes Martorell
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

4.  Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort.

Authors:  Marianne Foiselle; Susana Barbosa; Ophélia Godin; Ching-Lien Wu; Wahid Boukouaci; Myrtille Andre; Bruno Aouizerate; Fabrice Berna; Caroline Barau; Delphine Capdevielle; Pierre Vidailhet; Isabelle Chereau; Laetitia Davidovic; Jean-Michel Dorey; Caroline Dubertret; Julien Dubreucq; Catherine Faget; Guillaume Fond; Sylvain Leigner; Pierre-Michel Llorca; Jasmina Mallet; David Misdrahi; Emanuela Martinuzzi; Christine Passerieux; Romain Rey; Baptiste Pignon; Mathieu Urbach; Franck Schürhoff; Nicolas Glaichenhaus; Marion Leboyer; Ryad Tamouza
Journal:  Brain Behav Immun Health       Date:  2022-03-29

5.  Neurobiological Divergence of the Positive and Negative Schizophrenia Subtypes Identified on a New Factor Structure of Psychopathology Using Non-negative Factorization: An International Machine Learning Study.

Authors:  Ji Chen; Kaustubh R Patil; Susanne Weis; Kang Sim; Thomas Nickl-Jockschat; Juan Zhou; André Aleman; Iris E Sommer; Edith J Liemburg; Felix Hoffstaedter; Ute Habel; Birgit Derntl; Xiaojin Liu; Jona M Fischer; Lydia Kogler; Christina Regenbogen; Vaibhav A Diwadkar; Jeffrey A Stanley; Valentin Riedl; Renaud Jardri; Oliver Gruber; Aristeidis Sotiras; Christos Davatzikos; Simon B Eickhoff
Journal:  Biol Psychiatry       Date:  2019-09-23       Impact factor: 12.810

6.  A schizophrenia subgroup with elevated inflammation displays reduced microglia, increased peripheral immune cell and altered neurogenesis marker gene expression in the subependymal zone.

Authors:  Hayley F North; Christin Weissleder; Janice M Fullerton; Rachel Sager; Maree J Webster; Cynthia Shannon Weickert
Journal:  Transl Psychiatry       Date:  2021-12-15       Impact factor: 6.222

7.  Is there an association between inflammatory/anti-oxidant markers and the presence of psychotic symptoms or severity of illness in mood and psychotic disorders? A multi-centric study on a drug-free sample.

Authors:  Alice Caldiroli; Enrico Capuzzi; Jennifer L Barkin; Silvia Grassi; Cecilia Maria Esposito; Anna Maria Auxilia; Stefania Russo; Ilaria Tagliabue; Greta Silvia Carnevali; Francesco Mucci; Elena Invernizzi; Massimo Clerici; Massimiliano Buoli
Journal:  Brain Behav Immun Health       Date:  2022-03-19

Review 8.  Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets.

Authors:  Matej Ľupták; Danica Michaličková; Zdeněk Fišar; Eva Kitzlerová; Jana Hroudová
Journal:  World J Psychiatry       Date:  2021-07-19

Review 9.  Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits.

Authors:  David R Goldsmith; Mark Hyman Rapaport
Journal:  Front Psychiatry       Date:  2020-02-20       Impact factor: 4.157

10.  Common and disorder-specific upregulation of the inflammatory markers TRAIL and CCL20 in depression and schizophrenia.

Authors:  Flurin Cathomas; Stefan Kaiser; Federica Klaus; Karoline Guetter; Rebecca Schlegel; Tobias R Spiller; Erich Seifritz
Journal:  Sci Rep       Date:  2021-09-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.